Esch Robert E
Greer Laboratories, Inc., Lenoir, NC, USA.
J Allergy Clin Immunol. 2004 Feb;113(2):210-5. doi: 10.1016/j.jaci.2003.11.024.
The importance of fungal allergen products in the practice of clinical allergy is frequently underestimated. A wide variety of fungal species have been demonstrated to elicit allergic symptoms and to sensitize patients. The quality of fungal allergen preparations might have a significant effect on the specificity and sensitivity of diagnostic tests. Varying degrees of cross-reactivity have been shown among fungal genera, and the clinical relevance of this cross-reactivity has been neither fully appreciated nor applied to clinical practice. In addition, an increasing number of potentially new fungal allergen sources for which commercial extracts are not available are being identified. Manufacturers of allergen products have the formidable task of providing quality fungal allergen extracts that are routinely used for specific allergy diagnosis and treatment in the clinic. Currently there are no standardized fungal allergen products available in the United States because of inherent difficulties with manufacturing and standardizing fungal extracts. Without intervention, progress will not be forthcoming.
真菌过敏原产品在临床变态反应实践中的重要性常常被低估。已证实多种真菌物种可引发过敏症状并使患者致敏。真菌过敏原制剂的质量可能对诊断测试的特异性和敏感性产生重大影响。真菌属之间已显示出不同程度的交叉反应性，而这种交叉反应性的临床相关性尚未得到充分认识，也未应用于临床实践。此外，越来越多潜在的新真菌过敏原来源被发现，而目前尚无针对这些来源的商业提取物。过敏原产品制造商面临着一项艰巨的任务，即提供质量可靠的真菌过敏原提取物，这些提取物在临床上常规用于特异性过敏诊断和治疗。目前在美国没有标准化的真菌过敏原产品，因为真菌提取物的生产和标准化存在固有困难。如果不进行干预，就不会取得进展。
